Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Sarcoma 1Pancreatic Neoplasms 1Neoplasms, Plasma Cell 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1Meningioma 1Leukemia, Myelomonocytic, Chronic 1Leukemia 1Hemangiopericytoma, Malignant 1Central Nervous System Neoplasms 1Brain Neoplasms 1Anemia, Refractory, with Excess of Blasts 1Anemia, Refractory 1

Interventions

Doxorubicin 33Ifosfamide 23Gemcitabine 19pazopanib 18Cyclophosphamide 16Radiotherapy 15pembrolizumab 13Filgrastim 12Docetaxel 12Bevacizumab 10Vincristine 9Sirolimus 9Irinotecan 9Etoposide 9olaratumab 7eribulin 7Sorafenib 7Radiation 7temsirolimus 6Temozolomide 6Mesna 6Magnetic Resonance Spectroscopy 6Cisplatin 6tazemetostat 5cixutumumab 5Trabectedin 5Radiosurgery 5Nivolumab 5Ipilimumab 5Granulocyte Colony-Stimulating Factor 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Sarcoma × vatalanib × Clear all
NCT00348790 2018-10-26

Vatalanib in Treating Patients With Recurrent or Progressive Meningioma

Northwestern University

Phase 2 Completed
25 enrolled 10 charts
CNSSarcoma

Hemangiopericytoma, Malignant, Brain Neoplasms, Meningioma, Sarcoma, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡